Infliximab iv.

TENDER DESCRIPTION

Infliximab i.v. (OENO: 06053) Base quantity: 16 400 000 mg Option quantity: 8 200 000 mg Total framework quantity: 24 600 000 mg The CA enables the submission of multi-variant (alternative) offers under the following rules: The bidder may, in each alternative offer, propose different products (but products that are, in all respects, fully compliant with the technical description), and may also offer a different total offered amount for each alternative offer. The CA draws attention to the fact that the bidder may offer at most five variants, but it is not mandatory to offer more than one variant (it is only possible). Each of the variants offered by a single bidder participates in the evaluation at the same time. The variants offered by the same bidder compete with each other in the same part, so from the multiple variants offered by a single bidder, at most one variant may become the 1st, 2nd, 3rd or 4th placed in a given part; however, it is not excluded that, for a given part, the framework agreement may be concluded with the same bidder based on multiple offered variants according to the respective rankings. With regard to all variants, the professional minimum requirement…

TENDER BRIEF

TENDER DOCUMENTS